Cancer Research UK’s spin-out, GammaDelta Therapeutics, has been given approval to trial its unique T-cell therapy in the US.
Scientists are developing a new drug for treating acute myeloid leukaemia (AML), a type of blood cancer that affects around 3,100 people in the UK each year.
New research shows a type of aggressive blood cancer could be made more sensitive to chemotherapy using an antibiotic currently available to treat diarrhoea.
The targeted drug gilteritinib is now recommended for some adults with acute myeloid leukaemia (AML) on the NHS in England.
Leukaemia and head and neck cancer drugs have not been recommended for NHS use in England.
Researchers showed that the presence of leukaemia cells after initial chemotherapy could predict how well a patient subsequently fared.